Clinical Policy: pyrimethamine (Daraprim®)
Reference Number: ERX.NSMN.27
Effective Date: 12/15
Last Review Date: 09/16

Clinical policies are intended to be reflective of current scientific research and clinical thinking. This policy is current at the time of approval, may be updated and therefore is subject to change. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

Description
The intent of the criteria is to ensure that patients follow selection elements established by Envolve Pharmacy Solutions for the use of pyrimethamine (Daraprim®).

Policy/Criteria
It is the policy of health plans affiliated with Envolve Pharmacy Solutions® that pyrimethamine (Daraprim®) is medically necessary for members meeting the following criteria:

Initial Approval Criteria

I. Initial Therapy for Toxoplasmosis Infection – Active Disease (must meet all):
   A. Prescribed by or in consultation with an infectious disease specialist;
   B. Documented diagnosis of toxoplasmosis;
   C. Member meets one of the following:
      a. Age < 18 years;
      b. Failure of trimethoprim/sulfamethoxazole (TMP/SMX) as evidenced by lack of clinical improvement within 10-14 days or radiological deterioration during the first week despite compliant use, unless TMP/SMX is contraindicated;
   D. Daraprim is prescribed with sulfadiazine or clindamycin, along with leucovorin;
   E. Request does not exceed FDA approved maximum recommended dose and health plan approved daily quantity limit.

   Approval duration: Immunocompromised member: 6 weeks
   Immunocompetent member: 4 weeks

II. Primary Prophylaxis for Toxoplasmosis – Preventing 1st Episode (must meet all):
   A. Prescribed by or in consultation with an infectious disease specialist;
B. Request is for prevention for toxoplasmosis;
C. Member is HIV-infected with CD4 counts < 100 cells/mm³ and positive for *Toxoplasma gondii* IgG;
D. Documented contraindication to TMP/SMX;
E. Daraprim is prescribed with leucovorin and dapsone;
F. Request does not exceed FDA approved maximum recommended dose and health plan approved daily quantity limit.

**Approval duration: 6 months**

**III. Malaria and Malaria Prophylaxis:** This agent is not covered for these indications. *Daraprim is indicated for both treatment and prophylaxis of malaria. In the treatment of malaria, FDA-labeling recommends its use with fast-acting schizonticides (chloroquine or quinine). However, resistance to pyrimethamine is prevalent worldwide. Pyrimethamine is not recommended for use by the CDC treatment guidelines for the treatment or prophylaxis of malaria.*

**Continued Approval Criteria**

**I. Chronic Maintenance – Following Initial Therapy for Active Disease** (must meet all):

A. Previously received medication via health plan benefit or member has previously met all initial approval criteria;
B. Documentation of positive response to Daraprim;
C. Adherence to antiretroviral therapy (ART) as evidenced by pharmacy claims history or office notes;
D. Member is HIV-infected with CD4 counts < 200 cells/mm³ at any time in the previous 6 months;
E. Daraprim is prescribed with sulfadiazine or clindamycin, along with leucovorin;
F. Request does not exceed FDA approved maximum recommended dose and health plan approved daily quantity limit.

**Approval duration: 6 months**

**II. Primary Prophylaxis for Toxoplasmosis – Preventing 1st Episode** (must meet all):

A. Previously received medication via health plan benefit or member has previously met all initial approval criteria;
B. Member is HIV-infected with CD4 counts < 200 cells/mm³ at any time in the previous 3 months;
C. Daraprim is prescribed with leucovorin and dapsone;
D. Request does not exceed FDA approved maximum recommended dose and health plan approved daily quantity limit.

**Approval duration: 3 months**
Workflow Document

**Background**

**Description/Mechanism of Action**

Pyrimethamine is a folic acid antagonist. The rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and *Toxoplasma gondii*. Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans.

Although TMP/SMX is approved for pediatric patients 2 months of age and older, use in the treatment of toxoplasmosis is only indicated for adults > 18 years of age based on the study supporting its use for this condition.

**FDA Approved Indications**

Daraprim is FDA approved for the treatment of toxoplasmosis, treatment of acute malaria, and chemoprophylaxis of malaria.

**References**

8. Gandhi RT. Toxoplasmosis in HIV-infected patients. Bartlett JG (Ed), UpToDate, Waltham, MA. Accessed October 2015

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created.</td>
<td>11/15</td>
<td>11/15</td>
</tr>
<tr>
<td>No major content changes. Created workflow document. Updated references.</td>
<td>07/16</td>
<td>09/16</td>
</tr>
</tbody>
</table>